Compare Incyte Corporation (INCY) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SAP SE — how do they compare? Incyte Corporation trades at $113.39 (market cap $22.85B), while SAP SE trades at $214.85 (market cap $238.67B). The key difference: SAP SE is far larger — about 10.4× Incyte Corporation's market cap, and SAP SE pays a 1.38% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and SAP SE for 118 Days on average.
| INCY | SAP | |
|---|---|---|
Market Cap | $22.85B | $238.67B |
Volume | 1,927,029 | 2,252,662 |
Sector | Health | Technology |
52-Week High | $129.93 | $280.46 |
52-Week Low | $83.80 | $146.38 |
Typical Hold Time | 33 Days | 118 Days |
Enterprise Value | $18.35B | $237.42B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
SAP trades at $214.26, up 1.97% today, with a bullish technical signal from moving averages and a consensus analyst price target of $253.40. The company reported strong Q1 2026 earnings beat with EPS of $2.01, though Q2 2026 missed expectations. Revenue growth is robust, reaching $36.80B in 2025, with a net income margin of 20.41%. Recent news highlights AI-driven cloud revenue growth and partnerships, supporting positive sentiment.
Outlook remains positive with cloud and AI initiatives driving growth, but risks include competitive pressures and execution challenges. Analysts are predominantly bullish (51.16% buy ratings), seeing upside to the price target. Investors should monitor quarterly earnings consistency and margin trends amid industry volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
